Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Design Therapeutics (DSGN) Cash & Equivalents: 2020-2021

Historic Cash & Equivalents for Design Therapeutics (DSGN) over the last 1 years, with Sep 2021 value amounting to $357.7 million.

  • Design Therapeutics' Cash & Equivalents was N/A to $357.7 million in Q3 2021 from the same period last year, while for Sep 2021 it was $357.7 million, marking a year-over-year change of. This contributed to the annual value of $2.4 million for FY2020, which is N/A change from last year.
  • Latest data reveals that Design Therapeutics reported Cash & Equivalents of $357.7 million as of Q3 2021, which was down 3.55% from $370.8 million recorded in Q2 2021.
  • Design Therapeutics' Cash & Equivalents' 5-year high stood at $400.7 million during Q1 2021, with a 5-year trough of $2.4 million in Q4 2020.
  • Moreover, its 2-year median value for Cash & Equivalents was $364.2 million (2021), whereas its average is $282.9 million.